Quiz

Article

Clinical Quiz: Methotrexate for Pediatric Dermatoses

Author(s):

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

Clinical Quiz: Methotrexate for Pediatric Dermatoses

Methotrexate has been a common treatment for a number of pediatric and adult dermatoses for more than 70 years. An immunosuppressant, there are a number of supporting reasons to incorporate methotrexate into dermatologic care—but there are also pediatric-specific risks and outcomes to be wary of, as well.

In recognition of the Society for Pediatric Dermatology (SPD) 2024 Pre-AAD Meeting in San Diego, CA, this year, this latest HCPLive Clinical Quiz tests readers’ knowledge on the SPD’s recommended management of methotrexate in pediatric patients with conditions including atopic dermatitis, psoriasis, alopecia areata and more. The 5-question quiz is based on recommendations from the SPD’s Patient Perspectives handout, originally published in Pediatric Dermatology in 2023.

How would you fare in treating young patients with acne? Take the quiz below!

What is the most common side effect of methotrexate in children, and how can it be prevented?


Reference

Lalor L, Todd P. Society for Pediatric Dermatology. Patient Perspectives: What is methotrexate and how does it work? Pediatric Dermatology: Vol. 40, No. 5 (2023). https://pedsderm.net/site/assets/files/1028/spd_methotrexate_color-1.pdf

Related Videos
Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
Violeta Popov, MD, PhD | Credit: ACG
Satish Rao, MD, PhD | Credit: ACG
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
© 2024 MJH Life Sciences

All rights reserved.